AUA 2025 – Pfizer catches the Crest of a subQ wave
But sasanlimab's use looks set to remain narrow.
AUA 2025 – J&J scores in a new bladder cancer use
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
Aura bids to join the bladder cancer crowd
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Innate shows Bicycle the path for Nectin-4
While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.
